title: [Evaluation of side effects after intrabladder instillations of preparations in patients with superficial bladder carcinoma].
abstract: Permanent increase in neoplasm incidence including also bladder neoplasms makes physicians to search for new forms and methods of treatment. Application of new preparations entails in many cases appearance of side effects which are difficult to fight off and thus must be monitored constantly. To avoid complications which in case of BCG application are very burdensome and sometimes dangerous for patient it is necessary to intervene in due time. In the years 1990-1998 in Department of urology, Ministry of Internal Affairs and Administration Hospital in Łódź, 241 patients were treated due to superficial bladder carcinoma. In this group in 145 cases after carcinoma electroresection BCG suspension intrabladder infusion were applied. In 42 patients epirubicin, in 16 adriblastin intrabladder instillations were performed; 32 patients did not receive any preparation. A detailed history was taken from the patients before each next infusion, whereas blood was collected for testing before the first infusion and on the seventh day after completion of the therapy. Material for studies was collected before the first intrabladder infusion and on the seventh day after 4-week cycle completion. Side effects of the applied preparations were presented basing on toxicity grades acc. to WHO and divided into subjective and objective ones. The observation period comprised the time from the first infusion to the seventh day after the last infusion. In the group of 145 patients with applied BCG suspension 836 intrabladder instillations were performed. In 17 (12%) cases the treatment was stopped after 4 infusions due to intense dysuric symptoms. In the investigated group of patients strongly marked symptoms like polyuria (in 98% of patients), burning in urethra during miction (in 86%), haematuria and ill-being were observed. Objective symptoms were significantly marked and were not of importance in further management. In group II (epirubicin) and III (adriblastin) both subjective and objective effects were of insignificant percentage and were not of importance in the continuation of the treatment of superficial bladder carcinoma. Accurate subjective examination, careful analysis of the observed unfavourable symptoms, their intensity, close co-operation of the physician with the patient concerning full information on possible complications and side effects and personal procedure with them allow for safe and effective treatment of superficial bladder carcinomas with both BCG suspension and anthracycline antibiotics (in the form of intrabladder infusions).
authors.affiliation: Oddział Urologii Szpitala MSWiA, łodzi.
authors.forename: Piotr
authors.initials: P
authors.lastname: Kaczmarek
authors.forename: Jan
authors.initials: J
authors.lastname: Błaszczyk
authors.forename: Jan
authors.initials: J
authors.lastname: Kowalski
authors.forename: Jerzy
authors.initials: J
authors.lastname: Niemirowicz
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D004317:Doxorubicin / Q000009:adverse effects; D015251:Epirubicin / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011044:Poland; D013997:Time Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D001500:BCG Vaccine; D015251:Epirubicin; D004317:Doxorubicin